Biocryst Pharmaceuticals (BCRX) Total Liabilities (2010 - 2026)

Biocryst Pharmaceuticals has reported Total Liabilities for 17 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 9.33% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 9.33% YoY), and the FY2025 full-year result was $633.3 million, down 34.46% from the prior year.
• Total Liabilities for Q1 2026 stood at $1.0 billion, up from $633.3 million in the prior quarter.
• The five-year high for Total Liabilities was $1.0 billion in Q1 2026, with the low at $633.3 million in Q4 2025.
• Historically, Total Liabilities has averaged $872.9 million across 5 years, with a median of $918.6 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 94.1% — and 2025, when it plunged 34.46%.
• Biocryst Pharmaceuticals' Total Liabilities stood at $844.6 million in 2022, then gained by 15.14% to $972.5 million in 2023, then retreated by 0.63% to $966.4 million in 2024, then sank by 34.46% to $633.3 million in 2025, then soared by 60.88% to $1.0 billion in 2026.
• The last three Total Liabilities figures came in at $1.0 billion (Q1 2026), $633.3 million (Q4 2025), and $834.3 million (Q3 2025), per Business Quant data.